Name: Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation (Video) | JoVE Journal
Uploaded: 2017-08-14T14:00:00.000+00:00
Duration: 8 min 30 s
Description: Learn to quantify VWF-platelet string formation using an in vitro flow chamber model under fluid shear stress. This method enables real-time visualization of endothelial VWF release and platelet capture for studying hemostasis.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

Alison Michels is a recipient of a Frederick Banting and Charles Best Canada Graduate Scholarship from the Canadian Institutes of Health Research (CIHR). Laura L. Swystun is the recipient a CIHR fellowship. David Lillicrap is the recipient of a Canada Research Chair in Molecular Hemostasis. This study was funded in part by a CIHR operating grant (MOP-97849).

These studies were approved by the Research Ethics Board of Queen&#39;s University, Canada.
1. Endothelial Cell Stimulation
<ol>
	<li>Collagen-coat a 6-well tissue culture plate.
	<ol>
		<li>24 h in advance, coat a 6-well tissue culture plate at 37 &#176;C with 1 mL of collagen buffer (50 &#181;g/mL rat tail collagen type 1 with 0.02 M glacial acetic acid).</li>
		<li>Wash the wells twice with 2 mL of Hank&#39;s Balanced Salt Solution (HBSS). 
		NOTE: Plates can be wrapped in tin foil and stored in an airtight plastic bag at 4 &#176;C.</li>
	</ol>
	</li>
	<li>Seed the endothelial cells at a density of 1 x 106 cells per well in 2 mL of growth medium containing 10% fetal bovine serum (FBS). Incubate the cells for 24 h at 37 &#176;C (5% CO2). 
	NOTE: Here, blood outgrowth endothelial cells (BOECs) between passages 5 and 15 were used. BOECs were isolated from healthy volunteers with a wildtype VWF sequence using a method referenced in Starke et al.22 in a manner similar to one previously described by JoVE23.</li>
	<li>Remove the medium after 24 h and wash the cells with HBSS.</li>
	<li>Add 1 mL of serum-free medium (minimal essential growth medium without FBS) containing phorbol 12-myristate 13-acetate (PMA; 100 nM), unfractionated histone (UH), and HK or HR (all at 25 &#181;g/mL) to the cells for 2 h at 37 &#176;C (5% CO2). 
	NOTE: This concentration of histone was based on previous in vitro cytotoxicity reports by Xu et al.24 and Abrams et al.25 that used 50 &#181;g/mL.</li>
	<li>Collect the medium after 2 h and store it at -20 &#176;C until analysis.</li>
</ol>
2. VWF Quantification by Enzyme-linked Immunosorbent Assay (ELISA)
<ol>
	<li>Coat a microplate with 100 &#181;L of coating buffer (10 mM dibasic sodium phosphate and 145 mM sodium chloride, pH 7.2) containing 10 &#181;g/mL polyclonal anti-VWF antibody overnight at 4 &#176;C.</li>
	<li>Wash the plate three times with 250 &#181;L of wash buffer (10 mM dibasic sodium phosphate, 500 mM sodium chloride, and 0.1% Tween 20, pH 7.2).</li>
	<li>Dilute the medium samples 1:2 and 1:4 with wash buffer and use normal reference plasma for a standard curve, beginning at a 1:10 dilution.</li>
	<li>Plate 100 &#181;L of diluted samples and standards overnight at 4 &#176;C.</li>
	<li>Wash the plate three times with 250 &#181;L of wash buffer.</li>
	<li>Add 100 &#181;L of diluted anti-VWF, HRP-conjugated detection antibody (1.1 &#181;g/&#181;L in wash buffer) to the plate and incubate for 1 h at room temperature.</li>
	<li>Wash the plate and incubate for 10 min with O-Phenylenediamine dihydrochloride (OPD) reagent, as per the manufacturer&#39;s instructions.</li>
	<li>Stop the reaction with 100 &#181;L of 1 M H2SO4 and read the plate at 492 nm.</li>
</ol>
3. Solid-phase Histone-VWF Binding Assay
<ol>
	<li>Coat a microplate with histones diluted in 0.5% sodium deoxycholate 50 mM carbonate buffer (pH 9.6) to 10 &#181;g/mL overnight at 4 &#176;C.</li>
	<li>Wash the plate three times with 250 &#181;L of PBS supplemented with 0.1% Tween 20, incubating for 10 min between washes.</li>
	<li>Block the plate with 200 &#181;L of PBS supplemented with 0.1% Tween 20 and 1% bovine serum albumin (BSA) for 1 h at room temperature.</li>
	<li>Repeat step 3.2.</li>
	<li>Serially dilute plasma-derived human VWF/factor VIII complex from 200 mU/mL to 25 mU/mL in saline buffer (10 mM dibasic sodium phosphate, 500 mM sodium chloride, and 0.1% Tween 20, pH 7.2). Add 100 &#181;L to the plate for 2 h at room temperature.</li>
	<li>Repeat step 3.2.</li>
	<li>Detect the binding of VWF to immobilized histone using 100 &#181;L of a solution containing PBS-0.1% Tween 20 and 1:1,000 rabbit polyclonal anti-VWF antibody conjugated to HRP for 1 h at room temperature.</li>
	<li>Repeat step 3.2.</li>
	<li>Incubate the plate for 30 min with 100 &#181;L of OPD reagent and stop the reaction with 100 &#181;L of 1 M H2SO4. Measure the optical density at 492 nm.</li>
</ol>
4. Seeding Endothelial Cells onto Flow Chambers
<ol>
	<li>Load 0.5 mL of collagen-coating buffer (described in step 2.1) into a Luer-lock 1-mL syringe.</li>
	<li>Twist the Luer-lock end of the syringe onto the reservoir of a flow chamber slide.</li>
	<li>Press the plunger slowly until the entire lane is coated and each reservoir is full. Repeat for each lane and incubate the chamber at 37 &#176;C for 24 h.</li>
	<li>Aspirate the collagen-coating buffer with a 200 &#956;L pipette. Load another syringe with 1 mL HBSS and press the plunger slowly to wash each lane of the flow chamber. Aspirate the wash with a 200 &#956;L pipette at the opposing end of the flow chamber. Repeat twice.</li>
	<li>Pipette approximately 100 &#181;L of a 3 x 106 cells/mL endothelial cell (BOEC) solution in growth medium with 10% FBS into the lane of a flow chamber. 
	NOTE: The seeding density of endothelial cells exceeds the capacity of the chamber. This is to ensure maximal channel coverage; non-adherent cells are removed in the subsequent wash step.</li>
	<li>Incubate the chamber at 37 &#176;C for 24 h. Change the medium every 8-12 h using Luer-lock syringes (as in step 4.4). Ensure that there are no visible bubbles in the lanes.</li>
</ol>
5. Isolating Platelets from Human Whole Blood
<ol>
	<li>In a biological safety cabinet with a 30 G needle, add 300 &#181;L of acid-citrate dextrose buffer (85 mM trisodium citrate, 111 mM D-glucose, and 71 mM citric acid, pH 4.5) to an additive-free 3 mL blood collection vacutainer.</li>
	<li>Collect whole blood from healthy volunteers (free from anti-platelet and non-steroidal anti-inflammatory drugs for seven days) by venipuncture (three tubes of 3 mL each), following a protocol similar to that published by Bernardo et al26.</li>
	<li>Discard the first tube, as the initial tissue damage associated with the venipuncture can cause spontaneous platelet activation.</li>
	<li>Gently invert the vacutainers three times to mix the blood with anticoagulant.</li>
	<li>Centrifuge the vacutainers at 150 x g for 15 min at 24 &#176;C (room temperature).</li>
	<li>Slowly remove the platelet-rich plasma (supernatant) with a pipette in a biological safety cabinet and carefully transfer it to a 15-mL conical tube. Transfer the platelet-rich volume of each vacutainer to a single conical tube to avoid potential cross-activation. 
	NOTE: Platelet isolation should be performed in a biological safety cabinet to prevent bacterial contamination and potential artificial platelet and/or endothelial activation.</li>
	<li>Centrifuge the conical tubes at 900 x g for 10 min at 24 &#176;C (room temperature) to pellet the platelets.</li>
	<li>Pipette and discard the platelet-poor supernatant.</li>
	<li>Wash the pellet carefully with 1 mL of citrate-glucose-sodium (CGS) buffer (13 mM sodium citrate, 30 mM D-glucose, and 120 mM sodium chloride, pH 7.0). 
	NOTE: The platelets will appear in wisp-like formations when the CGS buffer is added and the pellet is gently resuspended. In samples contaminated by platelet activation, the platelets will not easily resuspend and will appear clumpy.</li>
	<li>Once fully resuspended, centrifuge the samples at 900 x g for 10 min at 24 &#176;C (room temperature).</li>
	<li>Remove the CGS wash buffer and resuspend the pellet in 3 mL of Tyrode&#39;s buffer (138 mM sodium chloride, 5.5 mM D-glucose, 12 mM sodium bicarbonate, 2.9 mM potassium chloride, and 0.36 mM dibasic sodium phosphate, pH 7.4). Ensure complete resuspension of the platelets and, if aggregations are observed, discard the sample.</li>
	<li>Add 1.5 &#181;L from a 20 mM DiOC6 stock solution (dissolve 57.25 mg in 5 mL of methanol) to each 3 mL conical tube of washed platelets for a final concentration of 1 &#181;M. 
	NOTE: DIOC6 is a green fluorescent mitochondrial dye used in this experiment to label platelets.</li>
	<li>Aliquot 1 mL of the washed platelet solution to three 1.5-mL microcentrifuge tubes. 
	NOTE: The platelet volume required for this experiment is calculated based on the size of the flow chamber, the desired shear stress, and the length of the experiment (step 6.5). This protocol can be adjusted as conditions change to ensure that there is enough volume for fluid flow.</li>
	<li>Use the washed platelets within 2 h of isolation.</li>
</ol>
6. Flow Apparatus Assembly
<ol>
	<li>Attach a 70 cm piece of sterile silicone tubing (interior diameter of 1.6 mm) to a male elbow Luer connecter at one end and a female Luer lock adaptor at the other.</li>
	<li>Connect the female Luer lock adaptor attached to the tubing to a 20 mL syringe.</li>
	<li>Repeat steps 6.1 and 6.2 twice to generate three identical syringe-tubing connections.</li>
	<li>Use a syringe pump to generate fluid flow. Input the following settings into the syringe pump: interior diameter of the syringe and flow rate. 
	NOTE: A 20-mL syringe has an interior diameter of 19.55 mm. The flow rate is calculated based on the desired shear rate/shear stress and the dimensions of the flow chamber. For the flow chamber used in the current study, to achieve 1 dyn/cm2 (observed in low venous shear), a flow rate of 9.37 &#181;L/min is required. Because of evidence linking histones to venous thrombosis, a moderate venous shear of 4.45 dyn/cm2 is selected. This is also based on the assumption that the buffer has a similar viscosity to water. The flow rate is then equal to 41.7 &#181;L/min. Equations used to calculate the flow rate for various flow chamber dimensions can be found at:
	<ol>
		<li>Set the pump to withdraw fluid using the button option on the syringe pump.</li>
	</ol>
	</li>
	<li>Load the three syringes attached to tubing on the syringe pump and tightly secure brackets around the syringes and plungers.</li>
	<li>Attach a male elbow Luer to both ends of a second 20 cm piece of sterile silicone tubing.</li>
	<li>Connect one elbow Luer to a blunted 18-gauge needle.</li>
	<li>Repeat twice, creating three identical intake systems for the three lanes of the flow chamber. 
	NOTE: The silicon tubing and Luers can be washed with 10% bleach followed by distilled water before reuse. It is not recommended to reuse the flow chambers.</li>
</ol>
7. Microscope Settings
<ol>
	<li>Use a spinning disk microscope equipped with a fully automated stage. Perform illumination with a laser launch that provides 405, 458, 491, 543, and 633 nm laser lines. Capture all images with a 20X objective. Adjust all parameters with the analysis software (http://www.well.ox.ac.uk/_asset/file/metamorph-basic-commands.pdf).</li>
	<li>Select the channel settings (emission filter: 520/35), with excitation at 491 nm, for acquisition. Set the electron multiplying charge-coupled device to an electron-multiplying gain of 150, with an exposure time of 200 ms, to obtain the full dynamic data range. 
	NOTE: Platelets are labelled with a green fluorescent dye, DiOC6, with wavelength maxima (excitation, 482 nm; emission, 504 nm).</li>
	<li>Adjust the 491 nm laser power to 20%.</li>
	<li>Mark the centre of all three lanes and select 1 &#956;m for z range and 0.5 &#956;m for step size. Select the number of time points (i.e., duration) and the time between images (i.e., interval) to capture an image every 10 s; select &#34;60 time points&#34; per slide. Set the microscope to capture images from the three lanes and save them to a designated experiment folder. 
	NOTE: Because the flow chamber has three lanes, the microscope will need to toggle between three positions to capture the images.</li>
</ol>
8. VWF-platelet String Formation
<ol>
	<li>Remove the culture medium from the flow chamber (from step 4) using the same technique as in step 4.4.</li>
	<li>Add 100 &#181;L of either histamine (25 &#181;M), PMA (100 nM), UH, HK, or HR (all at 25 &#181;g/mL) diluted in serum-free medium (as in step 1.4) to stimulate the BOEC monolayer for 15 min at room temperature and ambient O2/CO2. 
	NOTE: Although not necessary for VWF release, performing this stimulation at 37 &#176;C will improve VWF exocytosis27.</li>
	<li>Ensure that one of the three separate lanes of the flow chamber remain untreated as an experimental control.</li>
	<li>Remove the medium using a 1 mL syringe and replace it with 100 - 200 &#181;L of PBS to wash the secretagogues off of the endothelial monolayer.</li>
	<li>Mount the flow chamber onto a slide stand using vascular clips to secure the chamber in place.</li>
	<li>Attach the available male Luer connector on the end of the 70 cm tubing (connected to the syringe) to the reservoir of the flow chamber. Repeat for the two other flow chamber lanes.</li>
	<li>Start the syringe pump to remove the PBS wash. Pipette additional PBS into the opposing flow chamber reservoir to ensure that the lanes do not run dry.</li>
	<li>Observe the flow system for equivalent flow across all three lanes and then pause the syringe pump.</li>
	<li>Select an area to capture the images in about the middle of each lane, in roughly the same area between experiments. 
	NOTE: The person operating the microscope can be blinded to the experimental conditions. This step ensures that the microscope is focused prior to platelet flow (refer to step 7).</li>
	<li>Attach a female luer coupler<a> </a>to a 5 mL syringe and then to the free male luer connector (step 6.8) and submerge the blunted needle in the 1.5 mL microcentrifuge tube containing the washed platelet solution (step 5.13). Slowly draw the platelet solution through the tubing to ensure no air bubbles within the system.</li>
	<li>Remove the 5 mL syringe and attach the male Luer to the open reservoir of the flow chamber. Repeat for the three lanes.</li>
	<li>Restart the syringe pump and capture images during platelet flow using the microscope and protocol settings from step 7 for 10 min in the dark.</li>
	<li>After 10 min, disconnect the Luer from the intake tubing on the flow chamber reservoir and fill the reservoir with PBS to maintain flow over the endothelial monolayer.</li>
</ol>
9. VWF-platelet String Quantification
NOTE: The continuous flow of PBS is required to maintain the VWF-platelet string elongation for image analysis. Cessation of flow will result in the VWF becoming globular and will impair VWF-platelet string quantification. It is essential to top up each reservoir with PBS during image capture. HBSS can replace PBS if cell shrinking or detachment is observed during this step.
<ol>
	<li>Beginning with the first lane, capture 10 images per slide without overlap using a 20X objective lens around middle of the slide. Repeat this for each lane. 
	NOTE: The areas surrounding the reservoirs should be avoided due to turbulent shear stress.</li>
	<li>Using image processing software, adjust the brightness by clicking &#34;Image,&#34; &#34;Adjust,&#34; and &#34;Brightness/Contrast.&#34; Drag the scroll bar until the adhered platelets can be viewed well enough for quantification.</li>
	<li>Record a VWF-platelet string when three or more aligned platelets are observed in the image. Count all the VWF-platelet strings in an image. Repeat for all 10 images and average for the experiment. 
	NOTE: The person performing the quantification can be blinded to the experimental conditions. It is not necessary to co-stain for VWF, as this has been confirmed by independent studies8,28,29.</li>
	<li>Repeat the experiment a minimum of three times to evaluate each secretagogue.</li>
</ol>

The authors declare no competing financial interests.

While the physiological relevance of VWF-platelet strings remains controversial due to their rapid dissolution in the presence of the VWF-cleaving protease ADAMTS13, they serve as a quantifiable in vitro model of platelet recruitment by VWF to a site at which a thrombus might form in the presence of localized increases in histone levels5. Moreover, in pathologies lacking ADAMTS13 activity-such as thrombotic thrombocytopenic purpura (TTP)-or in inflammatory microenvironments-where ADAMTS13...

Thrombosis is a leading cause of mortality worldwide1 and can develop in response todysregulated platelet activation and thrombin generation in both veinsand arteries. Plasma levels of VWF are a key regulator of blood coagulation, whereby low levels (&#60;50%) result in the bleeding disorder known as von Willebrand disease (VWD)2 and high levels (&#62;150%) are associated with an increased risk of venous3 and arterial4 thrombosis.
VWF is a multimeric glycoprotein synthesized by megakaryocytes and endothelial cells and stored in platelet &#945;-granules and WPBs, respectively. Upon hemostatic challenge, VWF can be released from endothelial WPBs to tether circulating platelets to activated endothelial cells5 or exposed collagen on the vessel wall6. Anchoring of VWF to endothelial cells has been shown to be mediated by P-selectin7 and integrin &#945;v&#946;38. The subsequent release of platelet &#945;-granule stores can further increase localized VWF concentrations to stabilize platelet-platelet interactions for platelet plug formation, the scaffold needed for the propagation of the coagulation cascade and fibrin deposition. The platelet-binding activity of VWF is regulated by its multimeric structure, with high-molecular weight multimers possessing greater hemostatic activity9,10. In circulation, VWF also acts as a carrier for the coagulation factor VIII.
Fluid shear stress is an essential regulator of VWF physiology. In the absence of shear stress, VWF exists in a globular form, concealing binding domains for platelet glycoprotein Ib adhesion11. When shear stress is present, the cleavage site for a metalloprotease, A disintegrin and metalloprotease with thrombospondin motif (ADAMTS13), is exposed. ADAMTS13 cleaves naked and platelet-decorated VWF strings to regulate multimer size, thereby reducing its hemostatic activity12.
VWF is an acute-phase protein, and numerous stimuli, including hypoxia13, infection14, and proinflammatory cytokines, have been shown to mediate VWF release from endothelial cells. Similar to other inflammatory agents, extracellular histones have also been shown to induce systemic VWF release in mice15,16 and the activation of platelets in vitro17,18,19. This was shown to be dependent upon histone subtype, as differences in lysine and arginine content may influence function15. Our study aims to establish a flow chamber model to investigate the influence of lysine-rich (HK) and arginine-rich (HR) histone subtypes and secretagogues on endothelial VWF release and real-time platelet capture, potential early events in inflammation-induced thrombosis.
This flow chamber methodology recapitulates in vivo interactions between subendothelial collagen, endothelial cells, VWF, and platelets in an in vitro system that is visual, reproducible, and quantifiable. It allows for the real-time assessment of all aspects of the pathway that regulates VWF-platelet interactions, including WPB secretion, platelet activation, and VWF proteolysis. Studies of VWF under controlled shear stress conditions have been used to evaluate VWD mutations that impair VWF release and platelet-binding function20, WPB physiology21, and VWF cleavage by ADAMTS135. We use this methodology to quantify VWF-platelet string formation as a consequence of an inflammatory stimulus: extracellular histones.

<table><tbody><tr><td>Calf-thymus unfractionated histones (UH)</td><td>Worthington Biochemical</td><td>HLY</td><td>Reconstituted in serum-reduced media (5 mg/mL)</td></tr><tr><td>Calf-thymus lysine-rich histones (HK)</td><td>Sigma-Aldrich</td><td>H5505</td><td>Reconstituted in serum-reduced media (5 mg/mL)</td></tr><tr><td>Calf-thymus arginine-rich histones (HR)</td><td>Sigma-Aldrich</td><td>H4830</td><td>Reconstituted in serum-reduced media (5 mg/mL)</td></tr><tr><td>Phorbol 12-myristate 13-acetate (PMA)</td><td>Sigma-Aldrich</td><td>P8139</td><td>Reconstituted in DMSO (20 mM)</td></tr><tr><td>Histamine</td><td>Sigma-Aldrich</td><td>H7125-1G</td><td>Reconstituted in water (50 mg/mL)</td></tr><tr><td>3,3&#039; Dihexyloxacarbocyanine Iodide (DiOC6)</td><td>Invitrogen</td><td>D273</td><td>Reconstituted in methanol (20 mM)</td></tr><tr><td>Rabbit Anti-VWF Coating Antibody</td><td>DAKO</td><td>A0082</td><td>For VWF ELISA</td></tr><tr><td>Rabbit Anti-VWF Detection Antibody, HRP conjugated</td><td>DAKO</td><td>P0026</td><td>For VWF ELISA and histone-VWF binding assay</td></tr><tr><td>Nunc MaxiSorp flat-bottom 96-well microplates</td><td>eBioscience</td><td>44-2404-21</td><td>For histone-VWF binding assay</td></tr><tr><td>Immulon 4 HBX Flat Bottom Microtiter 96-Well Plates</td><td>Thermo Scientific</td><td>3855</td><td>For VWF ELISA</td></tr><tr><td>Humate-P</td><td>CSL Behring</td><td>N/A</td><td>Plasma-derived human von Willebrand factor/factor VIII complex</td></tr><tr><td>Normal Reference Plasma</td><td>Precision BioLogic</td><td>CCNRP-05</td><td>For VWF ELISA standard curve</td></tr><tr><td>O-Phenylenediamine dihydrochloride (OPD) reagent</td><td>Sigma-Aldrich</td><td>P8287</td><td>Equivalent product available through ThermoFisher Scientific (Catalogue Number: 34006)</td></tr><tr><td>EGM-2 BulletKit</td><td>Lonza</td><td>CC-3162</td><td>For culturing and initial seeding of BOEC</td></tr><tr><td>Hank&#039;s Balanced Salt Solution (HBSS)</td><td>ThermoFisher Scientific</td><td>14025092</td><td></td></tr><tr><td>Rat-tail Collagen Type 1</td><td>Corning</td><td>354236</td><td></td></tr><tr><td>Gibco Opti-MEM I Reduced Serum Media</td><td>ThermoFisher Scientific</td><td>31985070</td><td>For endothelial cell stimulations</td></tr><tr><td>METAMORPH Microscopy Automation and Image Analysis Software</td><td>Molecular Devices</td><td>N/A</td><td></td></tr><tr><td>BD Vacutainer Blood Collection Tubes, No Additive</td><td>BD Biosciences</td><td>366703</td><td></td></tr><tr><td>&amp;micro;-Slide III 0.1 (flow chambers)</td><td>Ibidi</td><td></td><td>This product has been discontinued. We suggest using &amp;micro;-Slide VI 0.1 (#80661) or 0.4 (# 80601) and recalculating flow rate and platelet volume needed to maintain a shear stress of 4.45 dyn/cm2</td></tr><tr><td>Silicone Tubing 1.6 mm ID: 5 m, sterilized</td><td>Ibidi</td><td>10842</td><td></td></tr><tr><td>Luer Lock Connector Female: natural Polypropylene, sterilized</td><td>Ibidi</td><td>10825</td><td></td></tr><tr><td>Elbow Luer Connector Male: white Polypropylene, sterilized</td><td>Ibidi</td><td>10802</td><td></td></tr><tr><td>Blunted 18G Needle</td><td>BD Biosciences</td><td>305180</td><td></td></tr><tr><td>20 mL syringes</td><td>BD Biosciences</td><td>302830</td><td></td></tr><tr><td>Syringe Pump</td><td>New Era Pump Systems Inc. NE-1600 Multi-PhaserTM</td><td>N/A</td><td></td></tr><tr><td>Quorum WaveFX- 4X1 spinning disk microscope</td><td>Quorum Technologies</td><td>N/A</td><td></td></tr><tr><td>Image Processing Software</td><td>ImageJ</td><td>N/A</td><td></td></tr></tbody></table>

investigating von willebrand factor pathophysiology using a flow chamber model of von willebrand factor-platelet string formation

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Von Willebrand factor (VWF) is a multimeric glycoprotein coagulation factor that mediates platelet adhesion and aggregation at sites of endothelial damage and that carries factor VIII in the circulation. VWF is synthesized by endothelial cells and is either released constitutively into the plasma or is stored in specialized organelles, called Weibel-Palade bodies (WPBs), for on-demand release in response to hemostatic challenge. Procoagulant and proinflammatory stimuli can rapidly induce WPB exocytosis and VWF release. The majority of VWF released by endothelial cells circulates in the plasma; however, a proportion of VWF is anchored to the endothelial cell surface. Under conditions of physiological shear, endothelial-anchored VWF can bind to platelets, forming a VWF-platelet string that may represent the nidus of thrombus formation. A flow chamber system can be used to visually observe the release of VWF from endothelial cells and the subsequent platelet capture in a manner that is reproducible and relevant to the pathophysiology of VWF-mediated thrombus formation. Using this methodology, endothelial cells are cultured in a flow chamber and are subsequently stimulated with secretagogues to induce WPB exocytosis. Washed platelets are then perfused over the activated endothelium. The platelets are activated and subsequently bind to elongated VWF strings in the direction of fluid flow. Using extracellular histones as a procoagulant and proinflammatory stimulus, we observed increased VWF-platelet string formation on histone-treated endothelial cells compared to untreated endothelial cells. This protocol describes a quantitative, visual, and real-time assessment of the activation of VWF-platelet interactions in models of thrombosis and hemostasis.

To directly assess the effect of histones on VWF release from endothelial cells, we exposed confluent BOECs to serum-free medium containing PMA (positive control), UH, HR, and HK for 2 h. We showed that HK induced a 2-fold increase in VWF protein (VWF:Ag) in the medium of treated endothelial cells (Figure 1). Interestingly, when BOECs were stimulated with UH and HR, there was less VWF:Ag detected in the medium than in the untreated condition. We hypothesized ...

In this paper, we describe a method to assess endothelial von Willebrand factor release and the subsequent platelet capture under fluid shear stress in response to inflammatory stimuli using an in vitro flow chamber system.

Von Willebrand factor (VWF) is a multimeric glycoprotein coagulation factor that mediates platelet adhesion and aggregation at sites of endothelial damage ...

The overall goal of this procedure is to observe and quantify von Willebrand factor or VWF-platelet string formation in response to secretagogues. This method can help answer key questions in Von Willebrand factor biology and wavo-palliative body pathophysiology. It also helps us answer questions about mutations that impair von Willebrand factor release and platelet binding function.The main advantage of this technique is that it recapitulates the in-vivo interactions between sub-endothelial collagen, endoetholial cells VWF and platelets in a visual and quantifiable in-vitro system. I feel the visual demonstration of this method is vital. The required microscopy steps for capturing VWF-platelet string formation under multiple simultaneous conditions in real time can be difficult to master by text alone.Begin by loading 0.5 milliliters of collagen coating buffer into a 1 milliliter luer lock syringe. Twist the end of the syringe onto the reservoir of a flow chamber slide and depress the plunger slowly until the entire lane is coated and each reservoir is full. Top up the reservoirs to ensure each one is full.When all of the lanes have been loaded, incubate the chamber at 37 degrees Celsius for 24 hours. The next day, use a 200 microliter pipette to remove the collagen coating buffer. Then rinse each lane with HBSS, aspirating the saline with a 200 microliter pipette.After the third round of HBSS has been discarded, add approximately three times 10 to the 6th Blood Outgrowth Endothelial Cells per milliliter in 100 microliters of growth medium, supplemented with 10%FBS to each lane of the flow chamber. Then return the chamber to the 37 degree Celsius incubator for 24 hours, changing the medium every eight to 12 hours. To assemble the flow apparatus, first attach one male elbow luer connector to one end of each of three 70 centimeter pieces of sterile silicone tubing.And attach one female luer lock adapter to the other end of each tube. Connect the female luer lock adapters to individual 20 milliliter syringes and program the syringe pump. Load the syringes onto the pump, and tightly secure brackets around the syringes and plungers.Then, attach individual male elbow luers to both ends of three different 20 centimeter pieces of sterile silicone tubing, and connect a blunted 18 gauge needle to one of each of the three elbow luers. Next, on a spinning disk microscope equipped with a fully automated stage, select the 20x objective and set the appropriate channel settings. To obtain the full dynamic data range, set the electron multiplying charge coupled device to an electron multiplying gain of 150 with an exposure time of 200 milliseconds.Adjust the 491 nano-meter laser power to 20%and use the microscope software to mark the center of all three lanes. Set the Z-range to 1.0 micrometers and the step size to 0.5 micrometers. Finally, select the duration and the interval to capture an image every 10 seconds at 60 time points per slide.To induce the formation of VWF-platelet strings replace the culture medium from three lanes of the flow chamber, with serum-free medium alone as a control, then the stimulant of interest diluted in 100 microliters of serum-free medium to the additional lanes. Then incubate the chamber for 15 minutes at room temperature. At the end of the stimulation period, wash all three of the lanes with 100 to 200 microliters of PBS, and use vascular clips to map the flow chamber onto a slide stand.Attach one male luer connector from the end of a piece of 70 centimeter tubing to each reservoir of the flow chamber. And start the syringe pump to remove the PBS wash. Pipette additional PBS into the opposing flow chamber reservoir to ensure that the lanes do not run dry.Once equivalent flow is confirmed, pause the syringe pump. Attach a 5 millileter syringe with a female luer lock coupler to the first free male luer connector. And submerge the blunted needle in a 1.5 milliliter micro-centrifuge tube containing flourescently labeled washed platelet solution.Slowly, draw the platelet solution through the tubing to ensure that there are no air bubbles within the system. Attach the male luer to the open reservoir of the flow chamber, and load the other two lanes with platelet solution, as just demonstrated. Check the flow system setup to ensure all connections are secure.Restart the syringe pump and image the platelet flow for 10 minutes in the dark. Then disconnect the luer from the intake tubing on the flow chamber reservoir. And fill the reservoir with PBS to maintain a gentle saline flow over the endothelial cell mono-layer.To quantify the VWF-platelet string formation, capture 10 images per slide from each lane without overlap from the middle of the slide. When all of the images have been obtained, open the image processing software and click image, adjust, and brightness contrast. To adjust the brightness of the first image, dragging the scroll-bar until the adhered platelets can be viewed well enough for quantification.Then, record a VWF-platelet string when three, or more, aligned platelets are observed and count all of the strings in the image. Following the initiation of flow conditions, the untreated cells demonstrate very few VWF-platelet strings compared to histamine, or PMA treated cells. Which exhibit an average of two to three strings per field of view.Moreover, histones, which activate platelets as well as endothelial cells induce the production of more VWF-platelet strings than untreated, or histamine, or PMA stimulated controls. While attempting this procedure, keep the platelets quiescent until the flow experiment by discarding the first blood draw collection tube, maintaining all the reagents at room temperature and using a gentle pipette-ing technique. Modifications can be made to this procedure to evaluate VWF-platelet string formation in the presence of leukocytes, platelet activating agents, or string dissolution by the cleaving enzyme atom TS13.After watching this video, you should have a good understanding of how to evaluate secretogogue-induced VWF-platelet string formation and in-vitro flow chamber model.

investigating-von-willebrand-factor-pathophysiology-using-flow

Research

JoVE Journal

Medicine

The platelet adhesion cascade takes place in the presence of shear flow, a factor not accounted for in conventional (static) well-plate assays. This article reports on a platelet-aggregation assay utilizing a microfluidic well-plate format to emulate physiological shear flow conditions.

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Source: Claes, J., et al, In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions. J. Vis. Exp. (2015).This video demonstrates a method for studying host-pathogen interactions using a micro-parallel plate flow chamber seeded with human primary endothelial cells. Following endothelial cell activation by an ionophore and perfusion with fluorescently labeled bacteria, the cells release von Willebrand factor (VWF), which binds bacterial adhesins under shear...

Micro-Parallel Plate Flow Chamber Model for Studying Bacterial Adhesion to Human Endothelial Cells

To study the interaction of bacteria with the blood vessels under shear stress, a flow chamber and an in vivo mesenteric intravital microscopy model are described that allow to dissect the bacterial and host factors contributing to vascular adhesion.

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions

Platelet transfusion and hemostasis was modeled using blood reconstitution and microfluidic flow chambers to investigate the function of blood banking platelets. The data demonstrate the consequences of platelet storage lesion on hemostasis, in vitro.

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

This paper describes an experimental model of hemostasis that simultaneously measures platelet function and coagulation. Platelet and fibrin fluorescence is measured in real-time, and platelet adhesion rate, coagulation rate, and onset of coagulation are determined. The model is used to determine platelet procoagulant properties under flow in concentrates for transfusion.

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

This work describes a fluorescence microscopy-based method for the study of platelet adhesion, spreading, and secretion under flow. This versatile platform enables the investigation of platelet function for mechanistic research on thrombosis and hemostasis.

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Leukocytes avidly interact with vascular cells and platelets after vessel wall injury or during inflammation. Here, we describe a straightforward laminar flow-based assay to characterize the molecular mechanisms that underlie the interactions between leukocytes and their cellular partners.

Laminar Flow-based Assays to Investigate Leukocyte Recruitment on Cultured Vascular Cells and Adherent Platelets

This study describes the microscopic monitoring of pneumococcus adherence to von Willebrand factor strings produced on the surface of differentiated human primary endothelial cells under shear stress in defined flow conditions. This protocol can be extended to detailed visualization of specific cell structures and quantification of bacteria by applying differential immunostaining procedures.

Pneumococcus Infection of Primary Human Endothelial Cells in Constant Flow

Platelet function under flow can be assessed and simulated hemostatic resuscitation can be modeled using a microfluidic device, which has applications in trauma and transfusion medicine.

Microfluidics in Assessing Platelet Function

This article outlines the protocol for quantifying the percentage of Tissue Factor (TF)-positive platelets using whole blood flow cytometry, assessing the protein: (1) intracellularly in resting conditions, and (2) on the cell surface, in both resting and activated conditions. Guidance is also provided for evaluating TF-positive platelets in platelet-rich plasma.

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

This work describes a microfluidic assay that uses shear stress to trigger thrombus formation in blood and characterizes the thrombus by multiple dimensions of readout. The assay can measure the prothrombotic tendency of blood samples, and is thus useful in disease diagnosis, drug discovery, as well as basic mechanistic studies related to thrombosis.

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Learn to quantify VWF-platelet string formation using an in vitro flow chamber model under fluid shear stress. This method enables real-time visualization of endothelial VWF release and platelet capture for studying hemostasis.

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation (Video) | JoVE Journal

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Explore More Videos